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Abstract Proteolytic cleavage of the amyloid protein from the
amyloid protein precursor (APP) by APP secretases is a key
event in Alzheimer’s disease (AD) pathogenesis. K-Secretases
cleave APP within the amyloid sequences, whereas L- and Q-
secretases cleave on the N- and C-terminal ends respectively. The
transmembrane aspartyl protease BACE has been identified as
L-secretase and several proteases (ADAM-10, TACE, PC7) may
be K-secretases. A number of studies have suggested that
presenilins could be Q-secretases, although this remains to be
demonstrated conclusively. Inhibition of L- and Q-secretase, or
stimulation of K-secretase, is a rational strategy for therapeutic
intervention in AD. ß 2000 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Alzheimer’s disease (AD) is characterised by the presence of
proteinaceous deposits in the brain, comprising extracellular
amyloid plaques and congophilic amyloid angiopathy and in-
tracellular neuro¢brillary tangles [1]. The main component of
the extracellular amyloid deposits is the amyloid protein (AL),
which is derived by proteolytic cleavage from the amyloid
protein precursor (APP), a type I transmembrane glycoprotein
[2].
The AL region of APP comprises a sequence of 42^43 ami-
no acid residues located partly within the ectodomain and
partly within the transmembrane domain of APP (Figs. 1
and 2). APP is cleaved by three types of proteases, which
are designated K-, L- and Q-secretases (Fig. 1). Processing by
L- and Q-secretase cleaves on the N- and C-terminal ends of
the AL region respectively, releasing AL, whereas K-secretase
cleaves within the AL sequence [3]. Q-Secretase cleaves at sev-
eral adjacent sites to yield AL species containing 39^43 amino
acid residues.
A substantial body of evidence indicates that accumulation
of AL in the brain, particularly longer species containing 42 or
43 residues (long AL), is an important step in the pathogenesis
of AD [4]. Genetic and biochemical studies on familial forms
of AD have shown that a variety of pathogenic mutations in
the APP gene and in genes encoding proteins known as pre-
senilins increase the production of long AL [5]. Long AL is
also more abundant in sporadic (non-familial) forms of AD
[6], suggesting that the accumulation of long AL is a common
mechanism underlying all forms of AD. Furthermore, trans-
genic mice with increased AL levels have some neurodegener-
ative changes (e.g. dystrophic neurites, gliosis) and cognitive
defects similar to AD (reviewed in [7,8]), which supports this
view. Long AL aggregates more readily than the more com-
monly produced AL40 species, and may seed the formation of
AL40 ¢brils, which ultimately act as a template for plaque
formation [9]. It is generally believed that aggregated AL is
neurotoxic, although the mechanism of neurotoxicity is not
well understood [4].
Because of their role in the production of AL, the APP
secretases have been under intense investigation. Recent stud-
ies have identi¢ed several candidate APP secretases. This re-
view describes the current status of research on APP secre-
tases and on secretase inhibitors which may prove useful for
AD therapy.
2. K-Secretase
A major route of APP processing is via the K-secretase
pathway, which cleaves on the C-terminal side of residue 16
of the AL sequence, generating an 83-residue C-terminal frag-
ment (C83) (Figs. 1 and 2) [10]. Subsequent cleavage by Q-
secretase releases a short peptide (p3) containing the C-termi-
nal region of the AL peptide (Fig. 1). The biological signi¢-
cance of p3 and its role, if any, in amyloidogenesis remains
obscure. As cleavage of APP by K-secretase destroys the AL
sequence, it is generally thought that the K-secretase pathway
mitigates amyloid formation, although this has not been dem-
onstrated unequivocally. In addition, the C-terminally trun-
cated form of APP released by K-secretase may have trophic
actions [11] which could antagonise the neurotoxic e¡ects of
aggregated AL [12].
Studies by Nitsch et al. [13] have shown that stimulation of
muscarinic receptors can increase cleavage of APP via the K-
secretase pathway, and inhibit AL production [14]. However,
at the time of writing, muscarinic receptor agonists have been
largely unsuccessful in the treatment of AD in clinical trials
[15], although not all promising muscarinic agonists have been
tested clinically.
The exact subcellular localisation of the K-secretase is un-
clear, although the trans-Golgi [16] has been proposed as one
of the sites of K-cleavage. More recently, a membrane-bound
endoprotease at the cell surface has been found to have K-
secretase-like activity [17]. However, the localisation of K-sec-
retase solely to regions of the late secretory pathway is di⁄-
cult to reconcile with the suggestion that stimulation of K-
secretase inhibits L-secretase processing [18] and that inhibi-
tion of K-secretase cleavage promotes AL production through
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the L-pathway [19], as the alternative L-secretase cleavage may
occur much earlier in the secretory pathway [20].
One possible explanation for the uncertainty about the lo-
calisation of K-secretase is that there may be more than one
enzyme. K-Secretase activity has both constitutive and regu-
lated components. Although the constitutive activity has not
yet been identi¢ed, regulated K-secretase cleavage appears to
be under the control of protein kinase C (PKC) [21]. Phorbol
esters increase K-secretion of APP above basal levels, while
PKC inhibitors leave a residual cleavage action [18].
Two members of the ADAM (a disintegrin and metallopro-
tease) family, tumour necrosis factor-K (TNFK)-converting
enzyme (TACE or ADAM-17) and ADAM-10, are candidate
K-secretases (Fig. 2). TACE cleaves pro-TNFK, releasing the
extracellular domain (TNFK) in a similar manner to APP.
The inhibition or knockout of TACE decreases the release
of the K-cleaved product sAPPK [22]. However, cells de¢cient
in TACE still have a residual K-secretase activity that cannot
be increased by phorbol esters [22]. Thus, TACE may play a
role in regulated PKC-dependent K-secretion.
Overexpression of ADAM-10 increased K-secretase cleav-
age of APP in a phorbol ester-inducible manner [17]. A dom-
inant-negative form of ADAM-10 with a point mutation in
the zinc-binding site was found to inhibit basal and stimulated
K-secretase activity, but did not totally abolish sAPPK pro-
duction [17]. ADAM-10 exists only in a proenzyme (inactive)
form in the Golgi, but becomes activated at the plasma mem-
brane [17]. Thus, TACE and ADAM-10 may both be K-sec-
retases.
Although the identity of the constitutive K-secretase activity
is not known, one possibility is the prohormone convertase
PC7 (Fig. 2). Overexpression of PC7 in HEK293 cells has
been found to increase sAPPK secretion, while overexpression
of K1-antitrypsin Portland (an inhibitor of precursor conver-
tases) was found to inhibit endogenous sAPPK production
[23]. However, as both TACE and ADAM-10 as initially syn-
thesised as proproteins, the possibility that PC7 acts upstream
as a pro-K-secretase cleaving enzyme cannot be excluded [23].
As it is likely that several proteases contribute to K-secre-
tase activity, it may be di⁄cult to regulate APP processing
pharmacologically through this pathway. However, most
studies aimed at developing inhibitors of AL production
have focussed on the two enzymes directly responsible for
cleaving AL from APP, L- and Q-secretase.
3. L-Secretase
A L-site APP cleaving enzyme (BACE or Asp2) has been
identi¢ed by several groups both by genetic screening and by
direct enzyme puri¢cation and sequencing [24^28]. BACE is
an unusual member of the pepsin family of aspartyl proteases,
which has an N-terminal catalytic domain, containing two
Fig. 1. Pathways of APP processing by K-, L- and Q-secretases. Cleavage by K-secretase (PC7, TACE or ADAM-10) produces sAPPK and a C-
terminal fragment C83. Both TACE and ADAM-10 can be activated by protein kinase C (PKC) which is regulated by the muscarinic acetyl-
choline (ACh) receptor. C83 is cleaved by Q-secretase to produce p3. Cleavage of APP by L-secretase (BACE) produces sAPPL and C99. Q-Sec-
retase, also believed to play a role in the proteolysis of Notch, cleaves C99 to release AL which has neurotoxic properties. Presenilins (PS) 1
and 2 have been proposed as Q-secretases.
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important aspartate residues, linked to a 17-residue trans-
membrane domain and a short C-terminal cytoplasmic tail
[24]. BACE contains four potential N-linked glycosylation
sites and a propeptide sequence at the N-terminus (Fig. 2).
Within the cell, BACE is expressed initially as a prepropro-
tein, and then e⁄ciently processed to its mature form in the
Golgi [29]. A related transmembrane aspartyl protease
(BACE2 or Asp1) [25] shows similar substrate speci¢city
[30] but is not highly expressed in the brain [31].
However, BACE possesses many of the features of L-secre-
tase. BACE can cleave full-length APP at Asp1 of the AL
sequence and also at Glu11, which is an alternative cleavage
site [24]. The Swedish NL mutation, which is known to en-
hance L-secretase cleavage [32], also promotes cleavage of
APP at Asp1 by BACE [24]. BACE is expressed coordinately
with APP in many regions of the brain, particularly in neuro-
nes, and has a subcellular distribution similar to that of L-sec-
retase [24]. Interestingly, the Flemish familial AD mutation
in APP increases production of AL from APP by BACE2
but not BACE [30], suggesting that BACE2 contributes
to AL production in individuals bearing the Flemish muta-
tion.
BACE has structural homology to a protease required for
the HIV life cycle and many of the inhibitors of this protease
can now be tested for their ability to inhibit BACE [33]. How-
ever, an important question is whether inhibition of BACE is
an appropriate strategy for therapeutic intervention in AD. It
is likely that BACE has several substrates (other than APP)
and that it has an important physiological function. Inhibition
of this function could have toxic consequences. Perhaps, the
development of BACE knockout mice may help to answer
some of the concerns about the physiological importance of
BACE and the consequences of inhibiting its activity.
4. Q-Secretase
Cleavage of the APP C99 fragment (Fig. 1) by Q-secretase is
the ¢nal step in the production of AL. The exact position of
cleavage by Q-secretase is critical for the development of AD.
Production of the more amyloidogenic long AL species by
Fig. 2. Functional domains of APP and putative APP secretases. The ¢gure also shows the amino acid sequence of APP around the amyloido-
genic region with the secretase cleavage sites indicated by arrows. Abbreviations: SP = signal peptide, CAT = catalytic domain, CYS = cysteine-
rich domain, S/T = serine/threonine domain, PRO = proprotein sequence, DIS = disintegrin domain, CYT = cytosolic domain, CRAM = crambin-
like domain, ^ denotes potential N-linked glycosylation sites, * denotes putative catalytic aspartate residues. Shaded regions show putative
transmembrane domains.
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cleavage by Q-secretase adjacent to residues 42 or 43 is closely
associated with disease pathogenesis [4,5].
Although the Q-secretase has not been identi¢ed, presenilin
(PS) 1 and 2 are two candidates. PSs are integral membrane
proteins with eight putative transmembrane domains, encoded
by genes on chromosomes 14 and 1 [34] (Fig. 2). A large
number of mutations have now been identi¢ed in PS, mostly
in PS1, which cause familial AD and many of these mutations
have been shown to cause an increase in the proportion of
long AL species [5,35].
There are several arguments supporting the view that PSs
are Q-secretase. As knockout of both PS1 and PS2 completely
inhibits all Q-secretase activity [36], this demonstrates that PSs
are required for Q-secretase activity. Furthermore, PSs are
localised to subcellular compartments (i.e. ER^Golgi) known
to be the site of Q-secretase processing [37]. Subcellular and
biochemical fractionation experiments have shown that PS
and Q-secretase copurify as a high molecular weight complex
[38]. In addition, Q-secretase inhibitors can a⁄nity-label PS
subunits [39,40] and both PSs reportedly bind to APP
[41,42]. Thus, if Q-secretase is not identical to the PS, then
the protease activity is at least intimately associated with PS
in vivo. Inhibitor studies show that Q-secretase is likely to be
an aspartyl protease [43]. Wolfe et al. [44] found that muta-
tion of two aspartate residues (Asp257 and Asp385) in the
transmembrane domain of PS1 inhibits Q-secretase activity.
Similar results have been obtained by mutating a correspond-
ing aspartate residue (Asp366) in PS2 [45], indicating that the
one or both aspartate residues may be important for cleavage
by Q-secretase (Fig. 2). Wolfe et al. [46] have suggested that
the two aspartate residues in PS1 form part of an active cata-
lytic site. However, in contrast to this idea, Capell et al. [47]
found that PS1 mutants lacking Asp257 secrete signi¢cant
amounts of AL.
However, the identity of Q-secretase as PS has not yet been
established. For example, PS has never been directly shown to
have protease activity. PS may simply be a regulatory subunit
of Q-secretase, or a protein that is somehow involved in the
tra⁄cking of proteins targeted to Q-secretase. Furthermore, it
is unclear how aspartates situated in a transmembrane domain
could participate in a hydrolytic cleavage. Not only would
transmembrane K-helices lack the ability to form active site
pockets typical of known enzymes, but also the lipid environ-
ment is unlikely to have enough water to facilitate hydrolytic
cleavage. Wolfe and coworkers [46] have proposed a model in
which the PS transmembrane domains form a pore, which
could allow water to enter the membrane. However, there is
as yet no experimental veri¢cation of this model.
Regulated intramembraneous proteolysis (RIP), similar to
Q-secretase cleavage of APP, has now been postulated to occur
in several membrane proteins [48]. However, the term RIP
may be misleading, as proteolytic cleavage within a membrane
has never been demonstrated directly. For example, it is pos-
sible that K- or L-secretase cleavage of APP results in move-
ment of the C-terminal polypeptide and exposure of the Q-
secretase sites to the aqueous environment.
A number of Q-secretase inhibitors have now been synthe-
sised [39]. However, as discussed for L-secretase, Q-secretase
may an important enzyme for the processing of other proteins
(e.g. Notch) [47]. Therefore, due regard needs to be taken of
the possibility that Q-secretase inhibitors may have unwanted
side e¡ects. Notch is involved in the regulation of neuronal
di¡erentiation, spermatogenesis, oogenesis and myogenesis,
and cleavage of the C-terminus by a Q-secretase-like activity
(regulated by PS) is an important step in its biological func-
tion [49]. It is possible that Q-secretase can be inhibited su⁄-
ciently to lower AL production in the brain without altering
the Notch signalling pathway. However, this remains to be
demonstrated in vivo.
5. Will inhibiting AL production be an e¡ective treatment for
AD?
Almost all of the work on APP secretases has been based
on the belief that inhibition of AL (especially AL42) produc-
tion will block or even reverse the cognitive decline in AD.
While there is strong evidence in favour of the amyloid hy-
pothesis of Small and McLean [4], it is not yet proven. It is
possible that the use of L- or Q-secretase inhibitors for AD
therapy will provide the ultimate test of this hypothesis. If the
cognitive decline in AD patients can be arrested using secre-
tase inhibitors, this will provide compelling evidence for a
direct role of AL in AD pathogenesis. Indeed, recent studies
involving a novel strategy for treatment of AD suggest that
removal of amyloid or AL from the brain may be of great
therapeutic bene¢t. APP transgenic mice immunised with AL
have been shown to have much lower AL amyloid in the brain
[50]. In addition, the pathologic change normally seen in these
mice can be inhibited by immunisation [50,51], supporting the
view that diminishing the amyloid burden will be of bene¢t.
Ultimately, the proof of this concept must rest with human
trials using secretase inhibitors.
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